Calithera tees up $84M IPO; Allozyne scrapped for parts;

@FierceBiotech: Cubist makes Euro landfall with a $400M purse for antibiotics R&D. More | Follow @FierceBiotech

@JohnCFierce:  FYI, I'm setting up some meets after the executive panel in Boston next month. Details | Follow @JohnCFierce

@DamianFierce: The @FierceBiotech Fierce 15 unveiling is happening live (and live-streamed) on Monday in Boston at #BPA14. Story | Follow @DamianFierce

@EmilyMFierce: Antibiotics R&D to get critical lift by executive order, Obama advisory group. Article | Follow @EmilyMFierce

> Calithera Biosciences has set terms for an $84 million IPO, looking to accelerate its treatments designed to shrink tumors by targeting their metabolisms. More

> Long-troubled biotech Allozyne is finally no more, Xconomy reports, as its parts have large been sold off to the likes of AstraZeneca's ($AZN) MedImmune. Story

> Biotech investor Frazier Healthcare has recruited former Incline Therapeutics and Cadence Pharmaceuticals ($CADX) exec David Socks to join its ranks as a venture partner. News

Medical Device News

@FierceMedDev: UDI architect shares compliance tips on eve of regulation's first deadline. More | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. Story | Follow @MichaelGFierce

@VarunSaxena2: Court ruling against FDA should enable more combination products to be classified as devices. Article | Follow @VarunSaxena2

@EmilyWFierce: San Francisco startup stirring up buzz for chicken egg facsimile, cataloging plant proteins to create new food model. Story | Follow @EmilyWFierce

> Apple HealthKit delayed by bug as major EHR players commit. Story

> British startup launches crowdfunding effort for 3-D printed orthotic devices. Article

Pharma News

@FiercePharma: Top-read pharma news Thurs: Put a lid on 'Low-T' drug use, FDA panel advises, threatening AbbVie, Lilly meds. Story | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. Story via FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Protein Sciences nabs stake in diabetes vax developer Diamyd. More from FierceVaccines | Follow @CarlyHFierce

> GSK China scandal resolved with $500M fine and suspended jail sentence. Story

> Europe approves Gilead's cancer drug Zydelig amid challenging pricing environment. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.